U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking

Regulations
Oct.10
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.

Key Points

The U.S. District Court for the Northern District of Texas stayed the Helix and NJOY challenge to FDA's 2021 PMTA rule on Oct. 8.

FDA announced Sept. 28 that it intends to reassess the PMTA regulatory framework and may initiate new rulemaking to replace the current system.

The parties said a new or amended FDA final rule could have a significant effect on the litigation.

R.J. Reynolds Vapor, Modoral Brands and American Snuff filed an unopposed motion to intervene on Sept. 8; the motion remained pending as of Oct. 9.


2Firsts

October 10, 2026

According to an Oct. 8 order from the U.S. District Court for the Northern District of Texas, U.S. District Judge James Wesley Hendrix granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations LLC and NJOY LLC to stay litigation challenging the agency's 2021 Premarket Tobacco Product Application, or PMTA, rule while FDA pursues anticipated rulemaking concerning the regulation.

Hendrix said the motion was granted for the reasons set out by the parties, citing FDA's anticipated rulemaking concerning the final rule at issue.

The court directed the parties to file a joint status report within 45 days and every 45 days thereafter.

Parties Sought Stay After FDA Announced PMTA Reassessment

The stay was jointly requested by the plaintiffs and the federal government rather than sought by one side over the other's objection.

The parties filed their joint motion on Sept. 29. Defendants include FDA, Acting FDA Commissioner Kyle Diamantas and the U.S. Department of Health and Human Services. Plaintiffs include Altria subsidiaries Helix Innovations and NJOY, the Texas Food & Fuel Association and retailers GWT Distributing LLC and Hometown Liquor LLC.

Their request followed FDA's Sept. 28 announcement that it intends to reassess its experience implementing the 2021 PMTA rule and evaluate changes to the regulatory framework, potentially including new rulemaking to replace the existing system.

FDA cited its experience under the 2021 rule, recent judicial developments, the growth of an unauthorized and unregulated market and the pace of new product introductions.

The agency also said it would continue processing PMTAs and applying the statutory appropriate-for-the-protection-of-the-public-health, or APPH, standard while evaluating the framework.

In seeking the stay, the parties said a new or amended final rule from FDA could have a significant effect on the litigation.

Helix and NJOY Seek Vacatur of 2021 PMTA Rule

Helix, NJOY and the other plaintiffs filed their complaint on Sept. 2 in the Northern District of Texas under the Administrative Procedure Act.

The challenged regulation is FDA's 2021 final rule, Premarket Tobacco Product Applications and Recordkeeping Requirements, which sets requirements for the content and format of PMTAs and establishes procedures governing the agency's review of applications.

The plaintiffs are asking the court to declare the rule unlawful, vacate and set it aside, remand it to FDA, and require the agency to adopt a new rule or review process that complies with what they say are the statutory deadlines established by the Tobacco Control Act.

They also seek preliminary and permanent injunctive relief preventing FDA from enforcing relevant premarket requirements against certain Helix and NJOY products with PMTAs that have been pending for more than 180 days.

The Oct. 8 stay does not rule on the merits of those claims and does not vacate the 2021 PMTA rule.

180-Day Review Period at Center of Challenge

A central issue in the complaint is how FDA applies the Tobacco Control Act's timeframe for acting on PMTAs.

The plaintiffs contend that the statute requires FDA to issue decisions within 180 days and that the agency's Acceptance Review, Filing Review and subsequent scientific review process has allowed applications to remain unresolved far beyond that period.

They allege FDA has “never complied” with the statutory system for reviewing new tobacco products and argue that the 2021 final rule compounded delays.

Those claims remain allegations. The court has not ruled that FDA violated the statutory 180-day requirement.

The plaintiffs also blame the regulatory system for contributing to the growth of unauthorized products in the U.S. market, arguing that prolonged reviews disadvantage companies participating in the PMTA process while unauthorized products remain available.

The court has not adopted that causal claim as a finding.

Helix Has Received Marketing Orders for Other Nicotine Pouch Products

Helix Innovations is Altria's nicotine pouch business and markets products under the on! brand, while NJOY operates Altria's e-cigarette portfolio.

FDA's public marketing-order records show that multiple Helix nicotine pouch products have received marketing authorization, including on! PLUS products in December 2025 and additional Helix decisions in August 2026.

The plaintiffs argue that the current rule has prevented the marketing of other Helix and NJOY smoke-free products whose applications remain pending.

FDA marketing authorization for one product does not extend to other products from the same manufacturer. Marketing orders apply only to the specific products covered by those decisions.

Reynolds Companies Seek to Join the Case

Six days after the original complaint was filed, R.J. Reynolds Vapor Company, Modoral Brands Inc. and American Snuff Company LLC filed an unopposed motion on Sept. 8 seeking to intervene in the Helix and NJOY litigation.

The three companies are part of Reynolds American.

They also filed a proposed intervenor complaint echoing key elements of the plaintiffs' challenge and seeking vacatur of the 2021 PMTA rule.

Reynolds has publicly argued that the existing PMTA framework has contributed to lengthy review delays and regulatory uncertainty and does not reflect Congress's intended review process.

As of Mealey's Oct. 9 report, Hendrix had not ruled on the companies' motion to intervene.

RJR therefore remains a proposed intervenor rather than a party whose intervention has already been formally granted by the court.

FDA Rulemaking Becomes Central to Next Stage of Case

When FDA announced its PMTA reassessment on Sept. 28, it specifically cited recent judicial developments, including litigation in the Northern District of Texas challenging the current regulatory framework.

The agency said it is considering a modernized framework intended to better reflect current market conditions and provide greater clarity and predictability.

FDA has not yet published the text of a proposed replacement rule, identified the specific provisions it intends to change or announced a timetable for completing new rulemaking.

The stay means the plaintiffs' effort to vacate the 2021 rule will not proceed on its previous litigation schedule while FDA's regulatory review develops. The parties must update the court every 45 days.

Any future proposed or final rule could affect which issues remain live in the case and the scope of any further judicial review.

For now, the court has made no merits determination on the legality of the 2021 PMTA rule, FDA's compliance with the 180-day review requirement or the injunctive relief sought by the plaintiffs.

Follow 2Firsts for timely updates on global tobacco and nicotine regulations, market developments and industry trends.

Cover Image generated by AI

2FIRSTS | Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
2FIRSTS | Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
www.2firsts.com

2FIRSTS | Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2FIRSTS | Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
www.2firsts.com

India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
The U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives said on September 23 that it has joined the interagency Trade Fraud Task Force to strengthen enforcement against illegal, misdeclared and smuggled vape and tobacco products. ATF will bring its authority under the Prevent All Cigarette Trafficking Act into the task force, including registration, reporting, shipping and record-inspection requirements covering interstate sales of electronic nicotine delivery systems. ATF said the move will strengthen its ability to trace illicit products from U.S. points of entry through domestic trafficking and distribution networks.
News
Sep.28 by 2Firsts Perspectives
New Zealand's Largest Vape Retailer Shosha Faces Advertising Probe Over Offshore Website and Local Fulfilment
New Zealand's Largest Vape Retailer Shosha Faces Advertising Probe Over Offshore Website and Local Fulfilment
New Zealand's Ministry of Health is reviewing its previous assessment of Shosha Global, an international website associated with vape retailer Shosha, after researchers found that the site displayed vaping products while fulfilling orders to New Zealand addresses. Radio New Zealand reported on November 13 that test purchases arrived within three days and shipping documents showed dispatch from Auckland. The researchers also found a store-stock tool listing only New Zealand locations and social media posts carrying local warning labels and cultural references. Shosha, which operates more than 125 stores in New Zealand, says Shosha Global serves overseas customers through an international partnership established in July 2025. No final regulatory finding against the website has been announced.
Regulations
Nov.17
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
The White House withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration (FDA) on November 17, 2026, a day before a scheduled Senate committee vote. Overton faced questions from Republican and Democratic senators over vaccines, abortion medication and flavored nicotine products. In May, the FDA granted its first marketing authorizations for non-tobacco, non-menthol e-cigarette flavors, including mango and blueberry pods from Glas. Republican Senator Susan Collins challenged recent authorizations for flavored vaping and nicotine pouch products during Overton's September confirmation hearing. The FDA remains under Acting Commissioner Kyle Diamantas.
FDA
Nov.18
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29